TRUSTEE EXPOSED: SHOSHANA SHENDELMAN
THE PROFILE
ROLE: ACTIVE COLUMBIA TRUSTEE (VP&S ’05)
STATUS: FACING SECURITIES FRAUD CLASS ACTION
KNOWN FOR: HARD-LINE SUPPORT FOR COLUMBIA’S CAPITULATION TO TRUMP
THE PEDIATRIC DRUG COVER-UP
While CEO of Applied Therapeutics, Shendelman oversaw clinical trials for govorestat, a drug intended to treat Galactosemia—a rare and life-altering PEDIATRIC DISEASE.
On Nov 27, 2024, the FDA issued a scathing Warning Letter addressed directly to Shendelman, citing "objectionable conditions" observed during inspections, including the deletion of electronic trial data and a failure to disclose dosing errors to regulators.
THE SHENDELMAN "STOCK DUMP"
After lying to the FDA, Shendelman hid these failures from investors while maintaining public "confidence" in the drug's approval. A lawsuit filed in New York federal court claims she sold 777,014 SHARES in a three-day window in August 2024.
THE PAYOUT: ~$4.7 MILLION.
Shortly after the FDA revealed the truth, the company's stock value crashed 90%.
THE COLUMBIA CONNECTION
Reports identify Shendelman as part of a hard-line faction on the Columbia Board in favor of capitulating to the Trump administration, cracking down on academic freedom, and supporting aggressive police intervention against student protesters. Shendelman has been on the board during a period of collapsed shared governance and is a threat to the university's fiduciary and ETHICAL STANDARDS.